ArticleEBioMedicine2025
Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanosensitive TRPV4 immunohistochemistry improves deep learning-based classification of ductal carcinoma in situ beyond H&E morphology.The journal of pathology. Clinical research · 2026Article
- Machine Learning-Enabled Intelligent Analysis of Surface-Enhanced Raman Scattering: Methods, Applications, and Perspectives.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuctal Carcinoma In Situ (DCIS) can progress to ipsilateral invasive breast cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that might progress to IBC cannot reliably be identified. Therefore, most patients with DCIS undergo treatment resembling IBC. To facilitate identification of low-risk DCIS, we developed deep learning models using histology whole-slide images (WSIs) and clinico-pathological data.
methodsWe predicted invasive recurrence in patients with primary, pure DCIS treated with breast-conserving surgery using clinical Cox proportional hazards models and deep learning. Deep learning models were trained end-to-end with only WSIs or in combination with clinical data (integrative). We employed nested k-fold cross-validation (k = 5) on a Dutch multicentre dataset (n = 558). Models were also tested on the UK-based Sloane dataset (n = 94).
findingsEvaluated over 20 years on the Dutch dataset, deep learning models using only WSIs effectively stratified patients into low-risk (no recurrence) and high-risk (invasive recurrence) groups (negative predictive value (NPV) = 0.79 (95% CI: 0.74-0.83); hazard ratio (HR) = 4.48 (95% CI: 3.41-5.88, p < 0.0001); area under the receiver operating characteristic curve (AUC) = 0.75 (95% CI: 0.70-0.79)). Integrative models achieved similar results with slightly enhanced hazard ratios compared to the image-only models (NPV = 0.77 (95% CI 0.73-0.82); HR = 4.85 (95% CI 3.65-6.45, p < 0.0001); AUC = 0.75 (95% CI 0.7-0.79)). In contrast, clinical models were borderline significant (NPV = 0.64 (95% CI 0.59-0.69); HR = 1.37 (95% CI 1.03-1.81, p = 0.041); AUC = 0.57 (95% CI 0.52-0.62)). Furthermore, external validation of the models was unsuccessful, limited by the small size and low number of cases (22/94) in our external dataset, WSI quality, as well as the lack of well-annotated datasets that allow robust validation.
interpretationDeep learning models using routinely processed WSIs hold promise for DCIS risk stratification, while the benefits of integrating clinical data merit further investigation. Obtaining a larger, high-quality external multicentre dataset would be highly valuable, as successful generalisation of these models could demonstrate their potential to reduce overtreatment in DCIS by enabling active surveillance for women at low risk.
fundingCancer Research UK, the Dutch Cancer Society (KWF), and the Dutch Ministry of Health, Welfare and Sport.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.